Company profile: VelosBio
1.1 - Company Overview
Company description
- Provider of clinical-stage, next-generation oncology therapeutics, developing first-in-class ROR1-directed treatments, including novel antibody-drug conjugates for hematologic and solid tumors; offerings include injection-based therapies such as WINREVAIR (sotatercept-csrk) and KEYTRUDA (pembrolizumab).
Products and services
- ROR1-directed Therapeutics: First-in-class treatments engineered to target the ROR1 cell-surface protein, expressed on many hematologic and solid tumors yet absent from normal tissues, transforming outcomes in oncology
- Novel Antibody-Drug Conjugates: Custom-engineered therapeutics developed to treat haematological cancers, reflecting a next-generation oncology focus and clinical-stage biopharmaceutical development
- KEYTRUDA (pembrolizumab) Injection: Injection-based therapy targeting certain medical diagnoses, produced as a pembrolizumab injection for patient treatment administration
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to VelosBio
Epsilogen
HQ: United Kingdom
Website
- Description: Provider of immuno-oncology therapies developing immunoglobulin antibodies for cancer, focusing on IgE-based drugs for solid tumors. Offerings include MOv18 IgE, targeting folate receptor alpha for ovarian cancer with Phase I safety and early clinical activity, and an IgEG fusion platform combining IgE and IgG to enhance potency and serum half-life, with in vitro and in vivo proof of concept.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Epsilogen company profile →
Traws Pharma
HQ: United States
Website
- Description: Provider of clinical-stage small molecule oral therapies, including investigational inhibitors for COVID-19 (TRX01/ratutrelvir) and pandemic influenza (TRX100/tivoxavir marboxil), and narazaciclib, a proprietary multi-kinase CDK4-plus inhibitor in trials for refractory endometrial and metastatic breast cancer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Traws Pharma company profile →
Vaxess
HQ: United States
Website
- Description: Provider of needle-free vaccine and therapeutic delivery solutions, offering the MIMIX applicator with patch for skin-based administration and silk fibroin biomaterials that create stable, biocompatible delivery systems, with a focus on improving access to vaccines.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Vaxess company profile →
Nuvation Bio
HQ: United States
Website
- Description: Provider of oncology-focused biopharmaceutical therapies addressing unmet needs, developing oral targeted candidates including Taletrectinib (CNS-active, selective next-generation ROS1 inhibitor for ROS1-positive NSCLC), Safusidenib (potent mIDH1 inhibitor for grades 2-3 IDH1-mutant glioma), NUV-868 (BD2-selective BET inhibitor targeting BRD4), and NUV-1511 (drug-drug conjugate candidate).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Nuvation Bio company profile →
NanoSmart Pharmaceuticals
HQ: United States
Website
- Description: Provider of platform drug delivery technologies for solid-tumor cancers, including a human-derived Anti-Nuclear Antibody targeting necrotic tumor tissue, ANA-conjugated lipid nanoparticles for direct API delivery to tumor sites, and a thermally sensitive nanoemulsion enabling stable storage and release at body temperature, plus licensing and partnerships to enhance existing cancer drugs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NanoSmart Pharmaceuticals company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for VelosBio
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to VelosBio
2.2 - Growth funds investing in similar companies to VelosBio
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for VelosBio
4.2 - Public trading comparable groups for VelosBio
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →